Sigyn Therapeutics, Inc.

OTCPK:SIGY Stock Report

Market Cap: US$5.1m

Sigyn Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jim Joyce

Chief executive officer

US$486.0k

Total compensation

CEO salary percentage93.6%
CEO tenureno data
CEO ownership20.0%
Management average tenure1.5yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Joyce's remuneration changed compared to Sigyn Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$486kUS$455k

-US$4m

Sep 30 2023n/an/a

-US$4m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$4m

Dec 31 2022US$502kUS$453k

-US$3m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

-US$3m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$527kUS$473k

-US$3m

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$2m

Mar 31 2021n/an/a

-US$1m

Dec 31 2020US$441kUS$419k

-US$1m

Compensation vs Market: Jim's total compensation ($USD486.04K) is about average for companies of similar size in the US market ($USD640.24K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Joyce (62 yo)

no data

Tenure

US$486,037

Compensation

Mr. James A. Joyce, also known as Jim, Ph.D. is a co-Founder of Sigyn Therapeutics, Inc. and also serves as its Chairman and Chief Executive Officer Inventor and served as its Chief Financial Officer. He f...

Leadership Team

NamePositionTenureCompensationOwnership
James Joyce
Co-founderno dataUS$486.04k19.96%
$ 1.0m
Craig Roberts
Co-founder & Directorno dataUS$256.46k15.97%
$ 820.5k
Gerald DeCiccio
Chief Financial Officer1.2yrsUS$128.77kno data
Charlene Owen
Director of Operations3.8yrsno datano data
Annette Marleau
Chief Scientific Officer1.8yrsno datano data
Johan Louw
Senior Vice President of Strategic Programs1.1yrsno datano data

1.5yrs

Average Tenure

64yo

Average Age

Experienced Management: SIGY's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
James Joyce
Co-founderno dataUS$486.04k19.96%
$ 1.0m
Craig Roberts
Co-founder & Directorno dataUS$256.46k15.97%
$ 820.5k
James Dorst
Independent Non-Employee Director2.3yrsno datano data
H. Humes
Member of Scientific Advisory Board2.9yrsno datano data
Alexander Yevzlin
Member of Scientific Advisory Board2.9yrsno datano data
Richa Nand
Independent Non-Employee Director2.3yrsno datano data
Michael Ryan
Directorless than a yearno datano data
Ajay Verma
Member of Scientific Advisory Board2.9yrsno datano data
Donald Hillebrand
Member of Scientific Advisory Board2.8yrsno datano data
Christopher Wetzel
Independent Non-Employee Director2.3yrsno data0.20%
$ 10.2k
Eric Stroup
Member of Scientific Advisory Board3.1yrsno datano data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: SIGY's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 13:58
End of Day Share Price 2025/01/16 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sigyn Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.